The future of probiotics is here, and it's all about traceability and functionality. At the Growth Asia Summit 2026, Lucas Chang, R&D Manager at TCI, made a compelling case for a paradigm shift in probiotic delivery. Chang argues that the traditional approach, focused on logistics and survival, is no longer sufficient. Instead, we must address the biological challenges that probiotics face once they reach their destination. This means building an 'evidence chain' that traces the impact of probiotics on the microbiome, bioactive compounds, host response, and measurable outcomes. This is particularly crucial for healthy aging, as the body's ability to handle pressure changes with age.
Chang highlights a fascinating study that revealed non-linear changes in the body across different age groups. The first transition occurs around 40, affecting lipid metabolism, alcohol metabolism, and cardiovascular health. The second transition happens around 60, impacting immune regulation, carbohydrate metabolism, and oxidative stress. This suggests that two people of the same age can have vastly different functional trajectories, with one person booking travel and the other doctor's appointments. Healthy aging, therefore, is not about avoiding these transitions but about building resilience between biological challenges.
TCI's TCR711, a patented spore-forming probiotic strain, is designed to target two common aging stresses: fat accumulation and alcohol. In a study involving adults with non-alcohol fatty liver disease (NAFLD), TCR711 improved liver-fat outcomes by 8.7% compared to placebo. This was accompanied by a shift in gut ecology, indicating that the probiotic's effects extend beyond the liver. The study also showed that TCR711 enhances alcohol clearance, with alcohol dehydrogenase- and aldehyde dehydrogenase-related capabilities detected in the strain.
Chang emphasizes that engineering a functional probiotic is not just about delivery but also about the desired outcome. Instead of starting with the strain, we should begin with the health outcome and functions we want to change. This approach, Chang argues, is more effective and aligns with our daily lives. For instance, TCI has developed liquid chocolate with probiotics, offering a convenient and tasty way to consume probiotics. This format not only ensures survival but also encourages daily habits that support gut health.
In conclusion, the next frontier of probiotics is about traceability and functionality. By addressing biological challenges and building an evidence chain, we can unlock the full potential of probiotics for healthy aging. Chang's insights at the Growth Asia Summit 2026 offer a compelling vision for the future of probiotic delivery, one that goes beyond survival and into the realm of targeted, functional outcomes.
